healthcare

healthcare Articles

Acorda Therapeutics shares dipped on Thursday after the company announced that the FDA would be delaying its Prescription Drug User Fee Act goal date for its review of the New Drug Application of...
Progenics Pharmaceuticals shares dropped on Thursday after the company announced late-stage results from its prostate cancer study.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data have been compared with the previous report, and short interest in...
The FDA is cracking down on smoking, but not what is traditionally considered smoking. The agency is going after e-cigarette manufacturers, as teen smokers (vapers) have reached epidemic levels.
Vital Thearpies shares were absolutely crushed on Wednesday after the company announced less-than-favorable results for its liver failure trial.
Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with Precision BioSciences.
Foamix Pharmaceuticals shares were last seen up early on Wednesday after the company announced a solid performance in its late-stage trial for moderate-to-severe acne.
Endocyte filed with the SEC for a secondary offering. In most cases where a company does this, we see the stock drop. However, in this case investors are cheering Endocyte and its secondary offering.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Endocyte shares made a solid gain early on Monday after the company announced an update from the FDA.
Clinical-stage biopharmaceutical company Kodiak Sciences has filed with the SEC regarding its initial public offering.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
Arrowhead Pharmaceuticals shares made a considerable gain early on Thursday after the firm announced data from its hepatitis B clinical trial with ARO-HBV.
MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry powder formulation of treprostinil, the active ingredient in...